Key Takeaways Travere Therapeutics rallied after the FDA waived the advisory committee for Filspari's FSGS sNDA.Approval could make Filspari the first treatment specifically indicated for FSGS patients.Phase III DUPLEX study showed sustained proteinuria remission, lowering the risk of kidney failure.Travere Therapeutics (TVTX) announced that the FDA, following further review of the supplemental new drug application (sNDA) for Filspari (sparsentan) in focal segmental glomerulosclerosis ("FSGS"), has determin ...